Strategic Report:


In pursuit of Mediclinic’s vision to be preferred locally and respected internationally, the Company offers an attractive investment case that aligns with seeking to achieve long-term value creation:

1 Given the anticipated impact of IFRS 16 accounting changes, the Board deemed it appropriate to proactively adjust the future payout ratio to 25%–35% of adjusted earnings.